Mark Crossley is a seasoned pharmaceutical executive with over 25 years of experience in the industry, specializing in global business strategy, commercial operations, and innovation in treatments for addiction and mental health. He began his career at Reckitt Benckiser, where he held progressively senior roles, including leading the company's pharmaceutical division and driving the successful commercialization of key opioid dependence therapies like Suboxone. Crossley later served as CEO of Mundipharma's International Business, overseeing operations across Europe, Asia, and Latin America, where he expanded market access for pain management and addiction treatments while navigating complex regulatory landscapes. In March 2018, Crossley was appointed Chief Executive Officer of Indivior Pharmaceuticals Inc., a specialty pharmaceutical company focused on addressing opioid use disorder. During his tenure, he spearheaded the U.S. launch of Sublocade, Indivior's groundbreaking long-acting buprenorphine injection, which received FDA approval and became a cornerstone of the company's portfolio. Under his leadership, Indivior achieved significant revenue growth, advanced pipeline development for novel therapies like perseris for schizophrenia, and strengthened its position as a leader in addiction medicine despite industry challenges, including litigation related to prior products. Crossley stepped down as CEO in April 2023 to pursue new opportunities, leaving a legacy of strategic transformation at Indivior. His efforts emphasized patient-centric innovation, operational efficiency, and sustainable growth, earning him recognition as a key figure in the fight against the opioid crisis. Post-Indivior, he continues to advise in the healthcare sector, drawing on his expertise to support emerging biopharma ventures.